Certain Class B Common Stock of Seer, Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2021.
July 26, 2021
Share
Certain Class B Common Stock of Seer, Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2021. These Class B Common Stock will be under lockup for 181 days starting from 27-JAN-2021 to 27-JUL-2021.
Details:
Selling stockholders, in connection with this offering, other stockholders subject to lock-up agreements entered into in connection with initial public offering were given the opportunity to have a portion of the shares subject to such lock-ups released from the transfer restrictions contained in such agreements. Any such stockholder who requested up to 5% of their existing holdings to be released from the lock-ups was required to enter a new lock-up agreement with respect to such stockholder’s remaining shares, which expire 180 days after the date of this prospectus and and 365 days after the date of this prospectus for those selling stockholders selling greater than 5% and up to 15% of their existing holdings, may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BofA Securities, Inc.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.